Investors
There is a need for a company bold enough to develop new treatments for autoimmune diseases that transform paradigms and clinical practice. We are that company.
Accelerated Path To Cures
There is an unmet clinical need for safer, more effective therapeutics for autoimmune diseases.
Our Products
Physicians
Tired of settling for mediocre therapies for patients living with autoimmune disorders? We are pursuing safer, more effective first-in-class oral therapeutics at an accelerated rate.
Learn More
Patients
You deserve treatment options that are safer, more effective, and less disruptive to your life. That is what drives Landos scientists and our team each and every day.
Learn More
Landos' unique core platform technology enables accelerated development of safer, more effective oral, first-in-class therapeutics for autoimmune diseases.
Technology
First Human Dosing of BT-11 Announced
Landos Biopharma Initiates Phase 1 Clinical Trial of BT-11, an Oral LANCL2 Agonist for Treatment of IBD
BLACKSBURG, VA, July 12, 2018 – Landos Biopharma, Inc., a clinical-stage[...]
Learn More
New Data from Landos Biopharma
Landos Biopharma Announces Human Translational Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018
BLACKSBURG, VA and WASHINGTON, DC June 5, 2018 – Landos[...]
Learn More
Landos Featured in Life Science Leader
Award winning Landos Biopharma, a biotech company dedicated to autoimmune disorders, has recently been featured in Life Science Leader.